Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trialsBirgit Sawitzki, Tewfik Miloud, David Game et al.|The Lancet|2020Cited by 445
Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinantsRoland J. Fuchs, Rüdiger Hehlmann, Michael Lauseker et al.|Leukemia|2017Cited by 339
A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapyChristoph K. Stein‐Thoeringer, Eran Elinav, Neeraj Saini et al.|Nature Medicine|2023Cited by 226